Avalon Investment & Advisory’s Jazz Pharmaceuticals JAZZ Stock Holding History

Avalon Investment & Advisory’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-21,575	Closed	-$3.63M	–	325
2018 Q3	$3.63M	Buy	21,575 +1,794	+9%	+$309K	0.1%	183
2018 Q2	$3.41M	Buy	+19,781	New	+$3.23M	0.1%	176
2016 Q3	–	Sell	-12,368	Closed	-$1.75M	–	313
2016 Q2	$1.75M	Buy	12,368 +3,048	+33%	+$449K	0.07%	139
2016 Q1	$1.22M	Buy	9,320 +1,120	+14%	+$139K	0.05%	140
2015 Q4	$1.15M	Buy	+8,200	New	+$1.14M	0.05%	142
2015 Q3	–	Sell	-4,229	Closed	-$745K	–	263
2015 Q2	$745K	Sell	4,229 -358	-8%	-$64.3K	0.03%	158
2015 Q1	$793K	Buy	4,587 +1,273	+38%	+$218K	0.03%	130
2014 Q4	$543K	Buy	+3,314	New	+$550K	0.02%	139

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Avalon Investment & Advisory's JAZZ Position: Q4 2018 in Review

Avalon Investment & Advisory sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2018, closing a stake of 21,575 shares — an estimated $3.63M sold.

Avalon Investment & Advisory first reported a position in JAZZ in Q4 2014 and held it in 8 quarters. The position peaked at $3.63M in Q3 2018. 417 funds tracked by Wall St. Rank hold JAZZ as of Q4 2018.

Avalon Investment & Advisory reported no remaining Jazz Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Avalon Investment & Advisory sold 21,575 Jazz Pharmaceuticals shares in Q4 2018, an estimated $3.63M.
Avalon Investment & Advisory first reported a position in Jazz Pharmaceuticals in Q4 2014 and held it in 8 quarters.
Avalon Investment & Advisory's Jazz Pharmaceuticals position peaked at $3.63M in Q3 2018.
417 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2018.

Based on Avalon Investment & Advisory's 13F filing for Q4 2018, filed 14 Feb 2019.